It is an honor to help support the Arthritis Foundation and to work closely with the Orthohealing Center.
POWAY, Calif. (PRWEB) November 26, 2019
Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, recently sponsored an event put on by the Arthritis Foundation and hosted by Dr. Steven Sampson and Dr. Danielle Aufiero of the Orthohealing Center in Los Angeles, California. The event, which took place on October 23, 2019, highlighted the ongoing efforts to promote research, educate the public, and provide support to people with arthritis.
Event attendees included medical doctors, physical therapists, chiropractors, and other medical professionals. Dr. Sampson presented current and evolving regenerative and stem cell therapies, including PSC’s FDA approved clinical trial to treat osteoarthritis in the knee with a person’s own stem cells. The Orthohealing Center is one of several approved clinical trial sites and is currently screening and enrolling patients in the clinical trial.
PSC CEO, Michael Dale, stated, “It is an honor to help support the Arthritis Foundation and to work closely with the Orthohealing Center. The Foundation
PSC provides stem cell therapy for clinical trial investigators and their patients, working within the FDA cell therapy regulations in order to assure consistent manufacturing, quality tested cells, as well as clinical trial and manufacturing oversite for safety and efficacy. PSC was founded by Robert Harman, DVM, MPVM and Michael Dale, both of whom also co-founded VetStem Biopharma and are both experienced serial entrepreneurs.
About Personalized Stem Cells, Inc.
Personalized Stem Cells was formed in 2018 to advance and legitimize human regenerative medicine. This privately held biopharmaceutical enterprise, based near San Diego (California), offers qualified physicians who enroll, an FDA compliant autologous stem cell product (from patient’s own fat tissue) for use in FDA approved clinical trials. PSC is driving development and adoption of stem cell and regenerative medicine within the FDA-IND process by providing cGMP manufactured, quality tested cells, and well-defined clinical trials. PSC has licensed a portfolio of over 70 issued patents in the field of regenerative medicine.
Share article on social media or email: